Los Angeles – October 16, 2026 -- Fengate Private Equity, a division of Fengate Asset Management, has partnered with Clinical Research of West Florida (CRWF), an independent trial site operator with more than 1,000 completed trials, in a deal with undisclosed terms.
Westcove Partners, LLC acted as exclusive financial advisor to CRWF. Its deal team comprised Managing Directors Justin Hand and Abe M'Bodj, Director Bill Bolding, Vice President Geno Catalano and Associate Andrew Hartono.
CRWF runs three Phase I-IV facilities across Tampa Bay
Founded in 1995, CRWF operates three Phase I-IV facilities in the Tampa Bay area. The company has conducted more than 1,000 trials across a broad range of therapeutic areas and has differentiated expertise in complex autoimmune and rheumatology indications.
CRWF cites its investigator base, proprietary patient database and preferred relationships with leading sponsors and contract research organizations (CROs) as the basis of its position in trial execution and patient enrollment.
Fengate manages more than $20 billion across private equity, infrastructure and real estate
Fengate Asset Management has more than $20 billion in assets under management. Its strategies span private equity, infrastructure and real estate, with offices and team members across Canada and the United States.
Owner Aydin Keskiner targets expansion into new markets and therapeutic areas
Aydin Keskiner, Owner and President of CRWF, said the company plans to continue building CRWF into a leading clinical research platform with Fengate.
Westcove Director Bill Bolding said Keskiner and his team have a clear vision for expanding the model across new markets and therapeutic areas. He said Fengate brings the resources and experience to accelerate that growth.